SwedenSweden

Thermo Fisher Scientific expands into autoimmunity diagnostics business with EUR2.5bn cash investment

20.05.2011

Uppsala – Thermo Fisher Scientific Inc. has signed a definitive agreement to acquire Phadia AB, a global leader in blood-based allergy and autoimmunity diagnostics, from European private equity firm Cinven, for EUR2.47 billion in cash. The transaction, which brings Cinven a profit of more than EUR1.2bn over the 2007 purchase price for the Swedish diagnostics specialist, is expected to be completed in the fourth quarter of 2011. With the deal, Thermo strengthens its speciality diagnostics business. Phadia reported 2010 total sales of EUR367m for its antigen testing platforms ImmunoCAP for allergy testing and EliA for autoimmunity testing, which runs on the Phadia250 platform, a walk-away automation system for fluorescence readout of the tests. Over the last three years Phadia (before 2004: Pharmacia Diagnostics AB) expanded by 10% (CAGR) globally but by 23% in the US market. Currently, Phadia is a global leader for in vitro allergy testing and a European leader in autoimmunity diagnostic testing. Autoimmune disorders is a growing segment of healthcare, with more than 100 million people worldwide suffering from autoimmune disorders such as rheumatoid arthritis or coeliac disease. 20% of people living in North America and Europe suffer from allergies. Thermo Fisher will leverage Phadia’s clinical marketing model to sell its specialty biomarker assays and other diagnostics products. Phadia will benefit from Thermo Fisher’s extensive healthcare market channels in the U.S. and strong presence in emerging markets.

SwedenSweden

12.03.2012

Gothenburg – Researchers at the Sahlgrenska Academy have discovered a previously unknown mechanism which helps intestinal bacteria to affect the formation of blood vessels. In a study of mice, the team led by Fredrik Bäckhed...

SwedenSweden

08.03.2012

Swiss Nestlé S.A. has extended its collaboration agreement with BioGaia AB. The world’s largest nutrition company is paying up to €50.8m for a perpetual licence to use BioGaia’s patented Lacto­bacillus reuteri in infant nutrition...

SwedenSweden

08.03.2012

Stockholm – Swedish drug delivery specialist Orexo AB has announced the intention to cut its headcount by 30% in order to reduce the company's burn rate. The personnel reduction by 35 people is expected to lower the costs by a...

SwedenSweden

07.03.2012

After a long period of negotiations, Sweden’s Orexo AB and Belgium’s Janssen Pharmaceutica have terminated their joint research programmes. “Unfortunately, we lack the funds to continue on our own to develop the OX-CLI and OX-ESI...

SwedenSweden

06.03.2012

Uppsala/Moscow – Vaccine adjuvant specialist Isconova AB is set to begin receiving royalties and product revenues from Russian partner VetBioChem. The veterinary medicine company has launched two new rabies vaccines for dogs and...

SwedenSweden

23.02.2012

Stockholm - Probiotics can help prevent diseases, Swedish researchers have found out. The results are in sharp contrast with all health claim judgements involving probiotics published by the EU's food watchdog EFSA up to now. The...

SwedenSweden

16.02.2012

Huddinge – Full stop for one of Sweden's most promising biotech companies. Karo Bio has terminated the trial of its late-stage cholesterol drug eprotirome and won't proceed with its plans to spin off its preclinical operations....

SwedenSweden

19.12.2011

Helsingborg/Exton – Swedish drug developer DuoCort Pharma AB has been purchased by US-based biopharmaceuticals maker ViroPharma Inc. ViroPharma paid around €25m up front, but DuoCort’s former owners could end up receiving €97m...

SwedenSweden

15.12.2011

Stockholm/Cologne – Researchers at the Swedish Karolinska Institute and the University of Cologne have identified a new protein-based defense mechanism against cancer (Struct. & Molec. Biology, doi: 10.1038/10.1038/nsmb.2188)....

SwedenSweden

15.12.2011

Craigavon/Uppsala – Irish Almac Discovery, a member of the Almac Group, will begin cooperating with Uppsala-based Beactica AB to develop new cancer drug candidates. In late November, the companies announced that Beactica’s Sprint...

Displaying results 1 to 10 out of 182

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-sweden/article/thermo-fisher-scientific-expands-into-autoimmunity-diagnostics-business-with-eur25bn-cash-investmen.html

Product of the week

Products

Events

All Events

Current issue

All issues